Article Sidebar

Submitted
Sep 9, 2024
Published
Sep 9, 2024
Download
PDF
Statistic
Read Counter : 26 Download : 14

Main Article Content

Abstract

Breast cancer is a worldwide health concern that necessitates continuous investigation into preventive measures. An active component of Nigella sativa (black seed), thymoquinone, has been the focus of extensive research. Pharmacology-wise, it is versatile. The current trials examining the potential of thymoquinone to prevent breast cancer are evaluated in this article. Anti-cancer, anti-inflammatory, and antioxidant in nature, thymoquinone exhibits great potential as a preventative agent against breast cancer. It prevents the production of cytokines and inflammatory mediators, both of which are known to promote malignancy. It is well known that oxidative stress contributes to the progression of cancer; however, the antioxidant properties of this substance mitigate this effect. This investigation investigates molecular pathways that are modulated by thymoquinone. The pathways of apoptosis, proliferation, and angiogenesis are investigated in this study. Although preclinical research has demonstrated the beneficial effects of phomoquinone on breast cancer cells, it is advisable to exercise caution when applying it in clinical settings. Due to the incomplete clinical trials of this medication's efficacy, further research is required to determine whether or not it has preventative properties. Due to the potential preventative applications of thymoquinone, its safety is also addressed in this analysis. It is the purpose of this synthesis to describe how thymoquinone inhibits breast cancer. It also emphasises the need for additional research into the therapeutic potential of this substance in order to improve global health.

Keywords

Thymoquinone Breast Cancer Prevention Nigella Sativa Anticancer Effects Molecular Mechanisms Preclinical Studies Clinical Trials Safety Herbal Medicine

Article Details

How to Cite
Sai Sri Jayanthi Emani, Sriniketh Chakravarthi, Trisha Reddy Chilkuri, Priyanka Peddamma, & Raja Rajeswari Kamisetti. (2024). Thymoquinone: A promising agent in the prevention of breast cancer. International Journal of Research in Pharmacology & Pharmacotherapeutics, 13(3), 325-331. Retrieved from https://ijrpp.com/ijrpp/article/view/563
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. 1. Adinew GM, Taka E, Mochona B, Badisa RB, Mazzio EA, Elhag R, Soliman KF. Therapeutic potential of thymoquinone in triple-negative breast cancer prevention and progression through the modulation of the tumor microenvironment. Nutrients. 2021 Dec 25;14(1):79.
  2. 2. Barkat MA, Ahmad J, Khan MA, Beg S, Ahmad FJ. Insights into the targeting potential of thymoquinone for therapeutic intervention against triple-negative breast cancer. Current Drug Targets. 2018 Jan 1;19(1):70-80.
  3. 3. Alobaedi OH, Talib WH, Basheti IA. Antitumor effect of thymoquinone combined with resveratrol on mice transplanted with breast cancer. Asian Pacific journal of tropical medicine. 2017 Apr 1;10(4):400-8.
  4. 4. Aumeeruddy MZ, Mahomoodally MF. Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquinone. Cancer. 2019 May 15;125(10):1600-11.
  5. 5. Almatroodi SA, Almatroudi A, Alsahli MA, Khan AA, Rahmani AH. Thymoquinone, an active compound of Nigella sativa: role in prevention and treatment of cancer. Current pharmaceutical biotechnology. 2020 Sep 1;21(11):1028-41.
  6. 6. Imran M, Rauf A, Khan IA, Shahbaz M, Qaisrani TB, Fatmawati S, Abu-Izneid T, Imran A, Rahman KU, Gondal TA. Thymoquinone: A novel strategy to combat cancer: A review. Biomedicine & Pharmacotherapy. 2018 Oct 1;106:390-402.
  7. 7. Khan A, Aldebasi YH, Alsuhaibani SA, Khan MA. Thymoquinone augments cyclophosphamide-mediated inhibition of cell proliferation in breast cancer cells. Asian Pacific Journal of Cancer Prevention: APJCP. 2019;20(4):1153.
  8. 8. Motaghed M, Al-Hassan FM, Hamid SS. Cellular responses with thymoquinone treatment in human breast cancer cell line MCF-7. Pharmacognosy research. 2013 Jul;5(3):200.
  9. 9. Ünal TD, Hamurcu Z, Delibaşı N, Çınar V, Güler A, Gökçe S, Nurdinov N, Ozpolat B. Thymoquinone inhibits proliferation and migration of MDA-MB-231 triple negative breast cancer cells by suppressing autophagy, Beclin-1 and LC3. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2021 Feb 1;21(3):355-64.
  10. 10. Shanmugam MK, Ahn KS, Hsu A, Woo CC, Yuan Y, Tan KH, Chinnathambi A, Alahmadi TA, Alharbi SA, Koh AP, Arfuso F. Thymoquinone inhibits bone metastasis of breast cancer cells through abrogation of the CXCR4 signaling axis. Frontiers in pharmacology. 2018 Dec 4;9:1294.
  11. 11. Odeh LH, Talib WH, Basheti IA. Synergistic effect of thymoquinone and melatonin against breast cancer implanted in mice. Journal of cancer research and therapeutics. 2018 Jun 1;14(Suppl 2):S324-30.
  12. 12. Khan MA, Tania M, Fu S, Fu J. Thymoquinone, as an anticancer molecule: from basic research to clinical investigation. Oncotarget. 2017 Aug 8;8(31):51907.
  13. 13. Ganji-Harsini S, Khazaei M, Rashidi Z, Ghanbari A. Thymoquinone could increase the efficacy of tamoxifen induced apoptosis in human breast cancer cells: An in vitro study. Cell Journal (Yakhteh). 2016 Jul;18(2):245.
  14. 14. Fakhoury I, Saad W, Bouhadir K, Nygren P, Schneider-Stock R, Gali-Muhtasib H. Uptake, delivery, and anticancer activity of thymoquinone nanoparticles in breast cancer cells. Journal of nanoparticle research. 2016 Jul;18:1-6.
  15. 15. Rajput S, Kumar BP, Banik P, Parida S, Mandal M. Thymoquinone restores radiation‐induced TGF‐β expression and abrogates EMT in chemoradiotherapy of breast cancer cells. Journal of Cellular Physiology. 2015 Mar;230(3):620-9.
  16. 16. Haiaty S, Rashidi MR, Akbarzadeh M, Bazmany A, Mostafazadeh M, Nikanfar S, Zibaei Z, Rahbarghazi R, Nouri M. Thymoquinone inhibited vasculogenic capacity and promoted mesenchymal-epithelial transition of human breast cancer stem cells. BMC complementary medicine and therapies. 2021 Dec;21:1-2.
  17. 17. Bashmail HA, Alamoudi AA, Noorwali A, Hegazy GA, Ajabnoor GM, Al-Abd AM. Thymoquinone enhances paclitaxel anti-breast cancer activity via inhibiting tumor-associated stem cells despite apparent mathematical antagonism. Molecules. 2020 Jan 20;25(2):426.
  18. 18. Alhmied F, Alammar A, Alsultan B, Alshehri M, Pottoo FH. Molecular mechanisms of thymoquinone as anticancer agent. Combinatorial Chemistry & High Throughput Screening. 2021 Nov 1;24(10):1644-53.
  19. 19. Zheng M, Mei Z, Junaid M, Tania M, Fu J, Chen HC, Khan MA. Synergistic Role of Thymoquinone on Anticancer Activity of 5-Fluorouracil in Triple Negative Breast Cancer Cells. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2022 Apr 1;22(6):1111-8.
  20. 20. Şakalar Ç, İzgi K, İskender B, Sezen S, Aksu H, Çakır M, Kurt B, Turan A, Canatan H. The combination of thymoquinone and paclitaxel shows anti-tumor activity through the interplay with apoptosis network in triple-negative breast cancer. Tumor Biology. 2016 Apr;37:4467-77.
  21. 21. Almajali B, Al-Jamal HA, Taib WR, Ismail I, Johan MF, Doolaanea AA, Ibrahim WN. Thymoquinone, as a novel therapeutic candidate of cancers. Pharmaceuticals. 2021 Apr 16;14(4):369.
  22. 22. Bhattacharjee M, Upadhyay P, Sarker S, Basu A, Das S, Ghosh A, Ghosh S, Adhikary A. Combinatorial therapy of Thymoquinone and Emodin synergistically enhances apoptosis, attenuates cell migration and reduces stemness efficiently in breast cancer. Biochimica et Biophysica Acta (BBA)-General Subjects. 2020 Nov 1;1864(11):129695.
  23. 23. Bashmail HA, Alamoudi AA, Noorwali A, Hegazy GA, AJabnoor G, Choudhry H, Al-Abd AM. Thymoquinone synergizes gemcitabine anti-breast cancer activity via modulating its apoptotic and autophagic activities. Scientific reports. 2018 Aug 3;8(1):11674.
  24. 24. Nasri S, Ebrahimi-Hosseinzadeh B, Rahaie M, Hatamian-Zarmi A, Sahraeian R. Thymoquinone- loaded ethosome with breast cancer potential: optimization, in vitro and biological assessment. Journal of nanostructure in chemistry. 2020 Mar;10:19-31.
  25. 25. Bhattacharya S, Ghosh A, Maiti S, Ahir M, Debnath GH, Gupta P, Bhattacharjee M, Ghosh S, Chattopadhyay S, Mukherjee P, Adhikary A. Delivery of thymoquinone through hyaluronic acid- decorated mixed Pluronic® nanoparticles to attenuate angiogenesis and metastasis of triple- negative breast cancer. Journal of Controlled Release. 2020 Jun 10;322:357-74.
  26. 26. Hajmomeni P, Sisakhtnezhad S, Bidmeshkipour A. Thymoquinone-treated mouse mesenchymal stem cells-derived conditioned medium inhibits human breast cancer cells in vitro. Chemico-Biological Interactions. 2023 Jan 5;369:110283.
  27. 27. Rajput S, Kumar BP, Dey KK, Pal I, Parekh A, Mandal M. Molecular targeting of Akt by thymoquinone promotes G1 arrest through translation inhibition of cyclin D1 and induces apoptosis in breast cancer cells. Life sciences. 2013 Nov 13;93(21):783-90.
  28. 28. Al-Mutairi A, Rahman A, Rao MS. Low doses of thymoquinone and ferulic acid in combination effectively inhibit proliferation of cultured MDA-MB 231 breast adenocarcinoma cells. Nutrition and Cancer. 2021 Feb 7;73(2):282-9.
  29. 29. Kabil N, Bayraktar R, Kahraman N, Mokhlis HA, Calin GA, Lopez-Berestein G, Ozpolat B. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer. Breast Cancer Research and Treatment. 2018 Oct;171:593-605.
  30. 30. Shabani H, Karami MH, Kolour J, Sayyahi Z, Parvin MA, Soghala S, Baghini SS, Mardasi M, Chopani A, Moulavi P, Farkhondeh T. Anticancer activity of thymoquinone against breast cancer cells: Mechanisms of action and delivery approaches. Biomedicine & Pharmacotherapy. 2023 Sep 1;165:114972.
  31. 31. Mehanna MM, Sarieddine R, Alwattar JK, Chouaib R, Gali-Muhtasib H. Anticancer activity of thymoquinone cubic phase nanoparticles against human breast cancer: Formulation, cytotoxicity and subcellular localization. International Journal of Nanomedicine. 2020 Dec 1:9557-70.
  32. 32. Khan MA, Tania M, Fu J. Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics. Drug discovery today. 2019 Dec 1;24(12):2315-22.
  33. 33. Ahmad R, Kaus NH, Hamid S. Synthesis and characterization of PLGA-PEG thymoquinone nanoparticles and its cytotoxicity effects in tamoxifen-resistant breast cancer cells. Springer International Publishing; 2020.
  34. 34. Khan MA, Zheng M, Fu J, Tania M, Li J, Fu J. Thymoquinone upregulates IL17RD in controlling the growth and metastasis of triple negative breast cancer cells in vitro. BMC cancer. 2022 Dec;22(1):1-1.
  35. 35. Alaaeldin E, Mostafa M, Mansour HF, Soliman GM. Spanlastics as an efficient delivery system for the enhancement of thymoquinone anticancer efficacy: Fabrication and cytotoxic studies against breast cancer cell lines. Journal of Drug Delivery Science and Technology. 2021 Oct 1;65:102725.
  36. 36. Bashmail HA, Alamoudi AA, Hegazy GA, Agabnoor GM, Noorwali A, Al-Abd AM. Thymoquinone attenuates breast cancer cell resistance to paclitaxel via targeting tumor associated stem cell population. Cancer Research. 2019 Jul 1;79(13_Supplement):2995-.
  37. 37. Kommineni N, Saka R, Bulbake U, Khan W. Cabazitaxel and thymoquinone co-loaded lipospheres as a synergistic combination for breast cancer. Chemistry and physics of lipids. 2019 Nov 1;224:104707.
  38. 38. Salam NM, Abd-Rabou AA, Sharada HM, Samea GG, Abdalla MS. Combination therapy of TRAIL and Thymoquinone induce breast cancer cell cytotoxicity-mediated apoptosis and cell cycle arrest. Asian Pacific Journal of Cancer Prevention: APJCP. 2021 May;22(5):1513.
  39. 39. El-Far AH, Salaheldin TA, Godugu K, Darwish NH, Mousa SA. Thymoquinone and its nanoformulation attenuate colorectal and breast cancers and alleviate doxorubicin-induced cardiotoxicity. Nanomedicine. 2021 May;16(17):1457-69.
  40. 40. Alkhatib MH, Bawadud RS, Gashlan HM. Incorporation of docetaxel and thymoquinone in borage nanoemulsion potentiates their antineoplastic activity in breast cancer cells. Scientific reports. 2020 Oct 22;10(1):18124.
  41. 41. Ibiyeye KM, Nordin N, Ajat M, Zuki AB. Ultrastructural changes and antitumor effects of doxorubicin/thymoquinone-loaded CaCO3 nanoparticles on breast cancer cell line. Frontiers in oncology. 2019 Jul 3;9:599.